Cyrus Badshah, MD, PhD

Merck & Co., Inc.

Disclosure(s): Merck & Co., Inc.: Stocks/Bonds; Merck Sharp & Dohme LLC: Current or former employee

Poster(s):

• 623 - Preliminary Dosing for Adolescent Hematopoietic Stem-Cell Transplant (HSCT) Recipients Based on Pharmacokinetic (PK), Safety, and Efficacy Data of Letermovir (LET) for Cytomegalovirus (CMV) Prophylaxis
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET